Open-Label Treatment Extension of Protocol MNTX 301

Completed · Phase 3

Conditions studied: Terminal Illness

In brief

This study is an open-label extension allowing patients who have completed Protocol MNTX 301 to continue to receive SC MNTX.

Key facts

Study ID

NCT01367600

Run by

Bausch Health Americas, Inc.

People needed

27

Starts

2003-02-01

Expected to finish

2005-02-01

Last updated by the study team

2019-11-27

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Completion of protocol MNTX 301; Double-Blind Treatment and Open-Label Treatment
• Negative pregnancy test

You may not qualify if…

• Women who are pregnant and/or nursing
• Any concurrent experimental drug therapy
• Evidence of fecal impaction
• Clinically significant active diverticular disease

Where it is running

• Progenics Pharmaceuticals — Tarrytown, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.